Almost as soon as TiGenix gained the European regulator’s recommendation for its allogeneic adipose-derived mesenchymal stem cell (MSC) therapy to treat complex perianal fistulas in Crohn’s disease, its partner Takeda moved to strike a deal. On December 15 the European Medicines
Agency (EMA)…

Para acessar a publicação na íntegra clique aqui

Fonte: 212 VOLUME 36 NUMBER 3 MARCH 2018 NATURE BIOTECHNOLOGY